UPDATE: Jefferies Upgrades ResMed (RMD) to Hold Following Survey
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
ResMed (RMD) PT Raised to $238 at RBC Capital
July 27, 2021 6:07 AM EDTRBC Capital analyst Craig Wong-Pan raised the price target on ResMed (NYSE: RMD) to $238.00 (from $223.00) while maintaining a Underperform rating.... More
ResMed (RMD) PT Raised to $285 at Needham & Company
July 26, 2021 3:47 PM EDTNeedham & Company analyst Mike Matson raised the price target on ResMed (NYSE: RMD) to $285.00 (from $267.00) while maintaining a Buy rating.
... MoreJPMorgan Downgrades ResMed (RMD:AU) (RMD) to Neutral
July 26, 2021 9:13 AM EDTJPMorgan analyst David Low downgraded ResMed (RMD:AU) (NYSE: RMD) from Overweight to Neutral with a price target of AUD33.50.
... More
